Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHACHAR PELES

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1568412930
CMS profile
252607
Location
PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$54,323.37

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHACHAR PELES

NPI 1568412930 · CMS profile ID 252607

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHACHAR PELES, NPI 1568412930, CMS profile ID 252607. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHACHAR PELES, NPI 1568412930, CMS profile ID 252607. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHACHAR PELES, NPI 1568412930, CMS profile ID 252607, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $54,323.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $770.0004/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672838887 CMS
Celgene Corporation $1,977.5004/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672853855 CMS
Janssen Biotech, Inc. $3.2204/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658641701 CMS
Seattle Genetics, Inc. $2.8804/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678797741 CMS
Seattle Genetics, Inc. $3.0504/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678797743 CMS
E.R. Squibb & Sons, L.L.C. $17.6504/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651308871 CMS
EISAI INC. $14.3904/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697004079 CMS
PFIZER INC. $14.2004/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673293761 CMS
Genentech USA, Inc. $18.2404/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681251741 CMS
Seattle Genetics, Inc. $22.4704/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678797735 CMS
Celgene Corporation $137.0604/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672845561 CMS
Genentech USA, Inc. $10.8804/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681146637 CMS
Lilly USA, LLC $15.1104/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658148631 CMS
Takeda Pharmaceuticals U.S.A., Inc. $639.7504/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697371673 CMS
Incyte Corporation $15.6304/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666273981 CMS
Celgene Corporation $1,155.0004/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672837990 CMS
Celgene Corporation $840.5604/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673014597 CMS
Celgene Corporation $1,977.5004/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673014603 CMS
Gilead Sciences, Inc. $12.9704/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681581907 CMS
PFIZER INC. $15.9404/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673297737 CMS
PFIZER INC. $0.8804/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673772517 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,620.0003/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697371645 CMS
Seattle Genetics, Inc. $1,200.0003/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678797773 CMS
Shire North American Group Inc $19.8603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637894553 CMS
Heron Therapeutics, Inc. $15.4203/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674510357 CMS
Merck Sharp & Dohme Corporation $14.0303/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695392385 CMS
Novartis Pharmaceuticals Corporation $15.0003/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659922421 CMS
Janssen Biotech, Inc. $1.1903/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658641693 CMS
Janssen Biotech, Inc. $17.0503/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658641697 CMS
Novartis Pharmaceuticals Corporation $16.8303/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659922423 CMS
Celgene Corporation $119.0903/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672867593 CMS
Amgen Inc. $7.4403/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663033223 CMS
Amgen Inc. $23.0503/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663033237 CMS
Amgen Inc. $23.0503/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663033243 CMS
Helsinn Therapeutics (U.S.), Inc. $12.2803/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655947063 CMS
AbbVie, Inc. $16.1603/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648019127 CMS
Janssen Biotech, Inc. $14.5003/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658641688 CMS
Celgene Corporation $1,977.5003/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672768231 CMS
Celgene Corporation $770.0003/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672797635 CMS
Regeneron Healthcare Solutions, Inc. $21.4503/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673455117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.8902/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697384759 CMS
Genentech USA, Inc. $16.2302/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681262369 CMS
Alexion Pharmaceuticals, Inc. $16.9502/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695601809 CMS
Janssen Biotech, Inc. $17.0702/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658641681 CMS
Janssen Biotech, Inc. $1.5602/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658641685 CMS
Astellas Pharma US Inc $12.8802/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655726691 CMS
Celgene Corporation $103.2002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672773447 CMS
Genentech USA, Inc. $12.2802/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681163967 CMS
Seattle Genetics, Inc. $15.0302/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678797731 CMS
Spectrum Pharmaceuticals Inc. $12.8902/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 639801171 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $54,323.37 220
PY2020 $13,779.97 107
PY2021 $8,669.64 126
PY2022 $11,762.15 173
PY2023 $13,003.66 184
PY2024 $18,774.35 170
PY2025 $11,735.27 219

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,523.50 2
PY2025 Principal investigator $878,753.65 202
PY2024 Principal investigator $851,406.62 209
PY2023 Principal investigator $892,313.76 260
PY2022 Recipient $4,500.00 1
PY2022 Principal investigator $545,008.17 92
PY2021 Principal investigator $202,816.75 86
PY2020 Principal investigator $203,140.61 56
PY2019 Principal investigator $190,691.85 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

204 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient F. Hoffmann-La Roche AG $939.17 12/10/2025 Covered Recipient Physician A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211538857
Principal investigator 1 Acerta Pharma LLC $650.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185541038
Recipient F. Hoffmann-La Roche AG $584.33 12/08/2025 Covered Recipient Physician A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211538862
Principal investigator 1 Epizyme, Inc. $411.25 11/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283461
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,466.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235993851
Principal investigator 1 Karyopharm Therapeutics Inc. $9,795.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664384
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664390
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664408
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664412
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664414
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664424
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664434
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,135.48 11/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1235993853
Principal investigator 1 Genentech, Inc. $156.00 10/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652369
Principal investigator 1 Genentech, Inc. $1,939.00 10/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652380
Principal investigator 1 ABBVIE INC. $2,265.00 10/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202514391
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 09/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664406
Principal investigator 1 Karyopharm Therapeutics Inc. $4,897.50 09/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664420
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 09/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664430
Principal investigator 1 ABBVIE INC. $1,045.00 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202507505
Principal investigator 1 ABBVIE INC. $3,913.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202504811
Principal investigator 1 ABBVIE INC. $7,462.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202504901
Principal investigator 1 Genentech, Inc. $1,058.40 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Polarix No dispute reported 06/30/2026 1211649222
Principal investigator 1 Celgene Corporation $43,565.97 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305646
Principal investigator 1 Epizyme, Inc. $4,200.00 08/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283435
Principal investigator 1 ABBVIE INC. $1,045.00 08/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202502056
Principal investigator 1 Epizyme, Inc. $4,200.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283105
Principal investigator 1 Epizyme, Inc. $35.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283111
Principal investigator 1 Epizyme, Inc. $35.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283115
Principal investigator 1 Epizyme, Inc. $37.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283119
Principal investigator 1 Epizyme, Inc. $37.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283137
Principal investigator 1 Epizyme, Inc. $125.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283153
Principal investigator 1 Epizyme, Inc. $37.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283155
Principal investigator 1 Epizyme, Inc. $35.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283157
Principal investigator 1 Epizyme, Inc. $35.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283159
Principal investigator 1 Epizyme, Inc. $4,200.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283163
Principal investigator 1 Epizyme, Inc. $37.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283203
Principal investigator 1 Epizyme, Inc. $37.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283205
Principal investigator 1 Epizyme, Inc. $37.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283207
Principal investigator 1 Epizyme, Inc. $35.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283209
Principal investigator 1 Epizyme, Inc. $37.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283211
Principal investigator 1 Epizyme, Inc. $35.00 07/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283221
Principal investigator 1 Genentech, Inc. $40.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652081
Principal investigator 1 ABBVIE INC. $100.00 07/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202499496
Principal investigator 1 Genentech, Inc. $6,170.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652115
Principal investigator 1 Genentech, Inc. $66.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651762
Principal investigator 1 Genentech, Inc. $81.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651945
Principal investigator 1 Genentech, Inc. $8,887.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652142
Principal investigator 1 Genentech, Inc. $375.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652228
Principal investigator 1 Epizyme, Inc. $4,200.00 07/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283107
Principal investigator 1 ABBVIE INC. $1,045.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202494159
Principal investigator 1 Genentech, Inc. $39.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651684
Principal investigator 1 Genentech, Inc. $688.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651739
Principal investigator 1 Genentech, Inc. $195.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651752
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651796
Principal investigator 1 Genentech, Inc. $155.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651817
Principal investigator 1 Genentech, Inc. $6,014.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651855
Principal investigator 1 Genentech, Inc. $155.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651878
Principal investigator 1 Genentech, Inc. $49.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651914
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651948
Principal investigator 1 Genentech, Inc. $65.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651961
Principal investigator 1 Genentech, Inc. $51.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652015
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652119
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652159
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652232
Principal investigator 1 Genentech, Inc. $54.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652257
Principal investigator 1 Genentech, Inc. $688.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652285
Principal investigator 1 Genentech, Inc. $40.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652294
Principal investigator 1 ABBVIE INC. $650.00 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202493789
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664402
Principal investigator 1 Karyopharm Therapeutics Inc. $9,795.00 06/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664404
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664426
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664432
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664392
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664416
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664428
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664436
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664438
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664452
Principal investigator 1 ABBVIE INC. $566.25 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202490319
Principal investigator 1 AstraZeneca UK Limited $8,577.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185541034
Principal investigator 1 ABBVIE INC. $1,045.00 06/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202489823
Principal investigator 1 Celgene Corporation $27,364.00 06/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1222305526
Principal investigator 1 Genentech, Inc. $125.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651012
Principal investigator 1 Genentech, Inc. $40.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651119
Principal investigator 1 Genentech, Inc. $45.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651155
Principal investigator 1 Genentech, Inc. $63.75 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651208
Principal investigator 1 Genentech, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651213
Principal investigator 1 Genentech, Inc. $56.25 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651245
Principal investigator 1 Genentech, Inc. $63.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651303
Principal investigator 1 Genentech, Inc. $66.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651323
Principal investigator 1 Genentech, Inc. $63.75 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651346
Principal investigator 1 Genentech, Inc. $101.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651351
Principal investigator 1 Genentech, Inc. $66.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651355
Principal investigator 1 Genentech, Inc. $40.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651392
Principal investigator 1 Genentech, Inc. $80.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651427
Principal investigator 1 Genentech, Inc. $66.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651536
Principal investigator 1 Genentech, Inc. $80.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651588
Principal investigator 1 Genentech, Inc. $63.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651600
Principal investigator 1 Genentech, Inc. $75.00 05/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651603
Principal investigator 1 Celgene Corporation $20,000.00 05/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1222306821
Principal investigator 1 Genentech, Inc. $44.00 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650973
Principal investigator 1 Genentech, Inc. $155.00 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651009
Principal investigator 1 Genentech, Inc. $63.75 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651031
Principal investigator 1 Genentech, Inc. $63.75 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651065
Principal investigator 1 Genentech, Inc. $40.00 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651298
Principal investigator 1 Genentech, Inc. $40.00 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651387
Principal investigator 1 Genentech, Inc. $75.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651083
Principal investigator 1 Genentech, Inc. $75.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651188
Principal investigator 1 Celgene Corporation $16,900.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222306703
Principal investigator 1 Epizyme, Inc. $100.00 05/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283087
Principal investigator 1 Genentech, Inc. $75.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650923
Principal investigator 1 Genentech, Inc. $40.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650956
Principal investigator 1 Genentech, Inc. $75.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651133
Principal investigator 1 Genentech, Inc. $75.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651148
Principal investigator 1 Genentech, Inc. $75.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651482
Principal investigator 1 Genentech, Inc. $63.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651485
Principal investigator 1 Genentech, Inc. $63.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651521
Principal investigator 1 ABBVIE INC. $1,045.00 05/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202481999
Principal investigator 1 Genentech, Inc. $40.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650979
Principal investigator 1 Genentech, Inc. $56.25 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651035
Principal investigator 1 Genentech, Inc. $5,441.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651073
Principal investigator 1 Genentech, Inc. $40.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651142
Principal investigator 1 Genentech, Inc. $56.25 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651341
Principal investigator 1 Celgene Corporation $42,699.33 04/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305520
Principal investigator 1 Genentech, Inc. $14,296.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651434
Principal investigator 1 ABBVIE INC. $637.00 04/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202475993
Principal investigator 1 Eli Lilly and Company $907.15 04/08/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187883696
Principal investigator 1 Eli Lilly and Company $976.45 04/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187889042
Principal investigator 1 ABBVIE INC. $1,183.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474756
Principal investigator 1 ABBVIE INC. $20,020.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474760
Principal investigator 1 ABBVIE INC. $2,912.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474764
Principal investigator 1 ABBVIE INC. $1,365.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474768
Principal investigator 1 ABBVIE INC. $1,274.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474781
Principal investigator 1 ABBVIE INC. $1,274.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474785
Principal investigator 1 ABBVIE INC. $16,562.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474789
Principal investigator 1 ABBVIE INC. $1,638.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202474797
Principal investigator 1 Celgene Corporation $39,415.00 04/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222305610
Principal investigator 1 ABBVIE INC. $1,045.00 04/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202473544
Principal investigator 1 Epizyme, Inc. $4,200.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283021
Principal investigator 1 Epizyme, Inc. $4,200.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283033
Principal investigator 1 Epizyme, Inc. $86.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283065
Principal investigator 1 ABBVIE INC. $650.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202467977
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,516.71 03/25/2025 Non-covered Recipient Entity
Florida Cancer Specialists
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235997357
Principal investigator 1 ABBVIE INC. $1,729.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464004
Principal investigator 1 ABBVIE INC. $4,186.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464008
Principal investigator 1 ABBVIE INC. $2,093.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464012
Principal investigator 1 ABBVIE INC. $819.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464020
Principal investigator 1 ABBVIE INC. $2,275.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464056
Principal investigator 1 ABBVIE INC. $4,186.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464059
Principal investigator 1 ABBVIE INC. $2,093.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464121
Principal investigator 1 ABBVIE INC. $3,640.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464125
Principal investigator 1 Karyopharm Therapeutics Inc. $50.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664394
Principal investigator 1 Karyopharm Therapeutics Inc. $19,590.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664396
Principal investigator 1 Karyopharm Therapeutics Inc. $43.75 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664400
Principal investigator 1 Karyopharm Therapeutics Inc. $22,851.25 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664410
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664418
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664440
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664444
Principal investigator 1 Karyopharm Therapeutics Inc. $7,346.25 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664454
Principal investigator 1 Karyopharm Therapeutics Inc. $500.00 03/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664456
Principal investigator 1 ABBVIE INC. $7,007.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202462984
Principal investigator 1 ABBVIE INC. $8,281.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463024
Principal investigator 1 ABBVIE INC. $11,921.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463079
Principal investigator 1 ABBVIE INC. $2,002.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463083
Principal investigator 1 ABBVIE INC. $7,007.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463182
Principal investigator 1 ABBVIE INC. $1,045.00 03/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202456683
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,245.14 02/25/2025 Non-covered Recipient Entity
Florida Cancer Specialists
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235997355
Principal investigator 1 Genentech, Inc. $63.00 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650596
Principal investigator 1 ABBVIE INC. $8,535.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202445809
Principal investigator 1 Genentech, Inc. $2,067.00 01/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Polarix No dispute reported 06/30/2026 1211649208
Principal investigator 1 ABBVIE INC. $91.00 01/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202443239
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/30/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664380
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/30/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664422
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/30/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664442
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/30/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664446
Principal investigator 1 AstraZeneca UK Limited $3,200.00 01/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185541040
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664382
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664386
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664388
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664398
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664448
Principal investigator 1 Karyopharm Therapeutics Inc. $2,500.00 01/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664450
Principal investigator 1 Genentech, Inc. $10,684.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650335
Principal investigator 1 Eli Lilly and Company $62,406.25 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187889036
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,723.75 01/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Nave Subjec No dispute reported 06/30/2026 1235993849
Principal investigator 1 Eli Lilly and Company $815.07 01/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187889662
Principal investigator 1 Acerta Pharma LLC $5,017.00 01/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185541036
Principal investigator 1 Eli Lilly and Company $96,560.26 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187889034
Principal investigator 1 Eli Lilly and Company $80,066.69 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187889466
Principal investigator 1 Genentech, Inc. $95.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650345
Principal investigator 1 Genentech, Inc. $125.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650376
Principal investigator 1 Genentech, Inc. $63.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650391
Principal investigator 1 Genentech, Inc. $156.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650683
Principal investigator 1 Genentech, Inc. $95.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650715
Principal investigator 1 Genentech, Inc. $80.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650766
Principal investigator 1 Genentech, Inc. $125.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650770
Principal investigator 1 Genentech, Inc. $1,376.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650775
Principal investigator 1 Genentech, Inc. $81.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650778
Principal investigator 1 Genentech, Inc. $158.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650785
Principal investigator 1 Genentech, Inc. $66.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650841
Principal investigator 1 ABBVIE INC. $650.00 01/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202435766
Principal investigator 1 ABBVIE INC. $728.00 01/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202435813
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,682.00 01/01/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190307947